Last reviewed · How we verify
bismuth tripotassium dicitrate
Bismuth tripotassium dicitrate, marketed by Astellas Pharma Europe B.V., is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence and the protection afforded by its patent, which helps maintain its competitive edge. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | bismuth tripotassium dicitrate |
|---|---|
| Also known as | De-Nol |
| Sponsor | Astellas Pharma Europe B.V. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bismuth tripotassium dicitrate CI brief — competitive landscape report
- bismuth tripotassium dicitrate updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI